TICKERNERD
Menu
ENLVENLVHealthcare · Biotechnology

ENLV Stock Forecast: Enlivex Ltd. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$1.39

The 1 Wall Street analysts covering Enlivex Ltd. hold a median 12-month price target of $1,280 — +91986.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 4 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.1M
Ticker Nerd rank
5/ 100
Median analyst target
$1,280
Analysts covering
1
Revenue$0.0
Operating income−$5.9M
Net income$1.2B
Free cash flow−$2.6M
Quarterly, 8 quarters to 31 Dec 2025 · latest quarter's figure shown
Ticker Nerd rank

ENLV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Enlivex Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
5/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Revisions
56
Volatility
24
Issuance
13
Growth
8
Accruals
8
Value
7
Quality
5
Momentum
1

Size (98): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ENLV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENLV, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $1,280Median $1,280High $1,280

The green dot is the last close — the median target sits +91986.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026HC Wainwright & Co.MaintainsBuy$20 → $80
3 Aug 2026HC Wainwright & Co.MaintainsBuy—
7 Apr 2026HC Wainwright & Co.MaintainsBuy$13 → $20
7 Apr 2026HC Wainwright & Co.MaintainsBuy—
12 Jan 2026HC Wainwright & Co.MaintainsBuy—
24 Nov 2025D. Boral CapitalDowngradeHold—
29 Oct 2025D. Boral CapitalMaintainsBuy—
26 Sept 2025D. Boral CapitalMaintainsBuy—
12 Sept 2025D. Boral CapitalMaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
22 Aug 2025D. Boral CapitalMaintainsBuy—
18 Aug 2025D. Boral CapitalMaintainsBuy—
29 July 2025D. Boral CapitalMaintainsBuy—
22 July 2025D. Boral CapitalMaintainsBuy—
21 Apr 2025D. Boral CapitalMaintainsBuy—
3 Apr 2025D. Boral CapitalMaintainsBuy—
24 Mar 2025HC Wainwright & Co.MaintainsBuy—
3 Mar 2025D. Boral CapitalMaintainsBuy—
7 Feb 2025D. Boral CapitalMaintainsBuy—
11 Dec 2024D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ENLV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

ENLV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Enlivex Ltd. (ENLV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 76% of US stocks

Price / sales
—
Price / book
0.0×

Cheaper than 93% of US stocks

EV / EBITDA
−0.6×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
162.9%

Higher than 98% of US stocks

Return on assets
−0.6%

Higher than 41% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Enlivex Ltd. (ENLV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Enlivex Ltd. has a market value of $2.1M and an enterprise value of $13.6M.

  • Revenue in the twelve months to 31 Dec 2025: $0.0.

  • Net income over the same four quarters: $1.2B.

  • Free cash flow in the twelve months to 31 Dec 2025: −$10.5M, after $67K of capital spending.

  • Shares outstanding: 15.8M.

  • Trailing P/E: 0.0×; forward P/E: −1.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Enlivex Ltd. employs 34 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Dec 2025 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

ENLV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENLVEnlivex Ltd.$2.1M5
SILOSilo Pharma, Inc.$2.1M20
BRTXBioRestorative Therapies, Inc.$2.1M8
SLXNSilexion Therapeutics Corp.$2.3M40
REVBRevelation Biosciences, Inc.$2.3M11
HCWBHCW Biologics Inc.$2.4M54
PPCBPropanc Biopharma, Inc.$1.8M47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Enlivex Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENLV news & analysis

Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response

GlobeNewsWire · 2 Nov 2026positive

Enlivex reported 12-month Phase I/IIa Allocetra trial data showing a clinically meaningful response in 79.2% of patients aged 64 and older in the treatment group, compared with 47.6% in the placebo group (p=0.027). The company said the response rates were consistent with those at three and six months, and plans to present the data at ACR Convergence on November 8, 2026.

Why it matters — The results provide an update on Allocetra’s reported durability of treatment response in older patients, a key data point for ENLV watchers following the trial.

Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

GlobeNewsWire · 28 Oct 2026positive

Enlivex said 135 of the 182 planned participants in its Phase 2b Allocetra trial for age-related moderate-to-severe knee osteoarthritis have been randomized and received their first injection. Enrollment is ongoing at sites in the United States and Europe, with topline six-month data expected by mid-2027.

Why it matters — The enrollment update marks progress in the trial, while its planned data timing gives ENLV watchers a milestone to follow.

Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal

GlobeNewsWire · 27 Oct 2026negative

Enlivex said it received a Nasdaq delisting notice dated October 26, 2026, because its closing bid price was below the $1.00 minimum requirement for 30 consecutive business days. The headline says the company intends to appeal.

Why it matters — ENLV watchers may want to note the Nasdaq listing-compliance issue and the company’s stated intention to appeal.

Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026

GlobeNewsWire · 22 Oct 2026neutral

Enlivex announced a 1-for-16 reverse split of its ordinary shares, effective October 27, 2026. The shares will trade on Nasdaq on a split-adjusted basis starting that day.

Why it matters — ENLV watchers may note the announced change to the share structure and the date it takes effect.

Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

GlobeNewsWire · 19 Oct 2026neutral

Enlivex announced an immediate cost reduction plan intended to substantially lower cash burn and focus resources on its Phase 2b trial of Allocetra™ for age-related moderate-to-severe knee osteoarthritis. The company expects to report topline six-month trial data by mid-2027.

Why it matters — The plan affects Enlivex’s spending and prioritization as it advances the trial, with six-month data expected by mid-2027.

FAQ

Frequently asked questions about ENLV stock

What is the ENLV stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Enlivex Ltd. have a median 12-month price target of $1,280, with estimates ranging from $1,280 to $1,280. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENLV stock a buy right now?

Of the 1 analysts covering Enlivex Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enlivex Ltd. 5 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENLV?

As at 4 Nov 2026, Enlivex Ltd. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

Will ENLV stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +91986.3% from the last close, and Ticker Nerd's factor model ranks Enlivex Ltd. 5 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENLV stock forecast for 2030?

No analyst covering Enlivex Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1,280 to $1,280 over the next 12 months.

What does Enlivex Ltd. do?

Enlivex Ltd. is a clinical-stage biotechnology company focused on macrophage reprogramming immunotherapy and inflammatory disease treatment.

What is the latest news on ENLV?

The most recent item we track (GlobeNewsWire, 2 Nov 2026): "Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response". Enlivex reported 12-month Phase I/IIa Allocetra trial data showing a clinically meaningful response in 79.2% of patients aged 64 and older in the treatment group, compared with 47.6% in the placebo group (p=0.027). The company said the response rates were consistent with those at three and six months, and plans to present the data at ACR Convergence on November 8, 2026.

Company

About Enlivex Ltd.

Enlivex Ltd. is a clinical-stage biotechnology company focused on macrophage reprogramming immunotherapy and inflammatory disease treatment. Its lead program, Allocetra, is designed to restore immune balance by reprogramming macrophages, with development efforts centered on conditions such as sepsis and osteoarthritis. The company’s current pipeline includes cell-based therapies for immune-related disorders and degenerative joint disease, reflecting its emphasis on novel approaches to immune modulation. Enlivex Ltd. operates from Ness Ziona, Israel, and serves the healthcare and biopharmaceutical markets through research, clinical development, and therapeutic innovation. The company’s role in the market is to advance experimental treatments that address unmet medical needs in inflammation-driven and immune dysregulation conditions.

34 employees · Israel · https://www.enlivex.com